FEDERAL COURT OF AUSTRALIA
Cipla Australia Pty Ltd v Novo Nordisk A/S [2024] FCA 1414
File number: NSD 516 of 2024 Judgment of: PERRAM J Date of judgment: 12 December 2024 Catchwords: PATENTS – patent for formulations of liraglutide – validity of extension of term of patent – where application for extension must concern a patent which discloses a ‘pharmaceutical substance per se’ under s 70 of the Patents Act 1990 – whether ‘pharmaceutical substance’ includes formulations of active ingredients and excipients – whether excipients required to be for distinct therapeutic use Legislation: Acts Interpretation Act 1901 (Cth) s 11B
Intellectual Property Laws Amendment Act 1998 (Cth)
Intellectual Property Laws Amendment Act 2006 (Cth)
Intellectual Property Laws Amendment Act 2015 (Cth)
Patents (World Trade Organization Amendment) Act 1994 (Cth)
Patents Act 1903 (Cth) s 84
Patents Act 1952 (Cth) ss 6, 90, 94
Patents Act 1990 (Cth) ss 70, 71, 77, 78, 119A, 192, 223(2), 230, Sch 1
Patents Amendment Act 1989 (Cth)
Therapeutic Goods Act 1989 (Cth) s 3
Customs (Prohibited Imports) Regulations 1956 (Cth) reg 2
Patents Amendment Bill 1988 (Cth)
Patents Amendment Bill 1989 (Cth)
Cases cited: Alphapharm Pty Ltd v H Lundbeck A/S [2008] FCA 559
Alphapharm Pty Ltd v H Lundbeck A/S [2014] HCA 42; 254 CLR 247
Baini v R [2012] HCA 59; 246 CLR 469
Boehringer Ingelheim International GmbH v Commissioner of Patents [2001] FCA 647; 112 FCR 595
Boehringer Ingelheim International v Commissioner for Patents [2000] FCA 1918
Commissioner of Patents v AbbVie Biotechnology Ltd [2017] FCAFC 129; 253 FCR 436
Commissioner of Stamps v Telegraph Investment Co Pty Ltd (1995) 184 CLR 453
H Lundbeck A/S v Alphapharm Pty Ltd [2009] FCAFC 70; 177 FCR 151
Hill v Zuda Pty Ltd [2022] HCA 21; 275 CLR 24
Novartis AG v Pharmacor Pty Ltd (No 3) [2024] FCA 1307
Pharmacia Italia SpA v Mayne Pharma Pty Ltd [2006] FCA 305; 69 IPR 1
Prejay Holdings Ltd v Commissioner of Patents [2003] FCAFC 77; 57 IPR 424
Project Blue Sky Inc v Australian Broadcasting Corporation [1998] HCA 28; 194 CLR 355
Spirit Pharmaceuticals Pty Ltd v Mundipharma Pty Ltd [2013] FCA 658; 216 FCR 344
Division: General Division Registry: New South Wales National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Number of paragraphs: 219 Date of last submissions: 11 November 2024 Date of hearing: 30 October-1 November 2024 Counsel for the Applicant/Cross-Respondent: Mr D Larish and Ms J McKenna Solicitor for the Applicant/Cross-Respondent: Maddocks Counsel for the Respondent/Cross-Claimant: Mr J Cooke SC and Ms M Evetts Solicitor for the Respondent/Cross-Claimant: Corrs Chambers Westgarth ORDERS
NSD 516 of 2024 BETWEEN: CIPLA AUSTRALIA PTY LTD
Applicant
AND: NOVO NORDISK A/S
Respondent
AND BETWEEN: NOVO NORDISK A/S
Cross-Claimant
AND: CIPLA AUSTRALIA PTY LTD
Cross-Respondent
ORDER MADE BY:
PERRAM J
DATE OF ORDER:
12 DECEMBER 2024
THE COURT ORDERS THAT:
1.The parties bring in short minutes of order to give effect to these reasons within…
Keep reading for free
Create a free CaseChat account to read Cipla Australia Pty Ltd v Novo Nordisk A/S and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2024] FCA 1414
- Decision Date
CaseChat Overview and Summary
The court examined the legislative history and current provisions of the Patents Act 1990 and found that the construction of "pharmaceutical substance" proposed by Cipla was contrary to its ordinary meaning and not supported by other provisions in the Act, legislative history, or case law. The court acknowledged a potential inconsistency with a High Court decision but ultimately decided that it was not bound by this obiter dictum, given it was not a considered statement. The court concluded that the formulations of liraglutide in question were not precluded from being "pharmaceutical substances" by virtue of being formulations. Additionally, the court rejected Cipla's alternative argument that the excipients in the formulations must have a distinct therapeutic use separate from the active ingredient, finding no such requirement under the Act.
The Federal Court of Australia ruled in favour of Novo Nordisk A/S, holding that the formulations of liraglutide in question were valid "pharmaceutical substances" under the Patents Act 1990. The court ordered the parties to submit minutes of order within seven days to give effect to the reasons provided.
Orders
Orders of the court
1. The parties bring in short minutes of order to give effect to these reasons within 7 days.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi